Actively Recruiting
Dupilumab Therapy for EGIDs
Led by Children's Hospital of Fudan University · Updated on 2025-12-02
20
Participants Needed
1
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-center observational study to investigate the efficacy and tolerability of dupilumab in children with refractory eosinophilic gastrointestinal disorders.
CONDITIONS
Official Title
Dupilumab Therapy for EGIDs
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of Refractory Peptic Ulcers
- Clinical diagnosis of Refractory Eosinophilic Gastrointestinal Disorders
You will not qualify if you...
- Active Helicobacter pylori infection at present
- Inflammatory bowel disease
- Parasite infection
- Cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
201102
Shanghai, China
Actively Recruiting
Research Team
Y
Ying Huang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here